BioNTech hikes COVID-19 vaccine output to 2B doses in 2021—and plans a bigger label, too Vaccines aren't enough. We need more COVID-19 treatments, too HHS expands COVID-19 public health emergency until April, preserving key telehealth flexibilities Genentech CEO says partnerships, speedier trials among pandemic's 'silver linings' Biden aims to release all available COVID-19 shots in departure from Trump strategy UHS details impact of fall cyberattack on patient volumes as COVID-19 could impact payer mix Synairgen's inhaled interferon for COVID-19 enhances short, harmless version of virus entry point: study Teladoc projects 2020 revenue to reach $1.1B as it expands virtual primary care Centene's Neidorff says insurer planning for a 'different mix' of care utilization due to COVID-19 Merck KGaA snaps up mRNA manufacturer AmpTec as pandemic vaccines unlock platform's future Featured Story | By Fraiser Kansteiner BioNTech pitched its latest pandemic battle plan on Monday at the J.P. Morgan Healthcare Conference: producing 2 billion doses globally, up from its original 1.3 billion-dose goal. Meanwhile, the Pfizer partner is looking to roll out an expanded list of approvals and a more temperature-stable formulation, too. read more |
| |
|---|
|
| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Top Stories By Amirah Al Idrus The two vaccines and multiple therapeutics cleared for emergency use aren't nearly enough to stop COVID-19. We need an arsenal of drugs that work in different ways to attack a complex, multifaceted illness, speakers on a Fierce JPM Week panel said. read more By Robert King HHS has extended for another 90 days the COVID-19 public health emergency set to expire later this month, keeping in place major flexibilities for telehealth. read more By Carly Helfand Since the COVID-19 pandemic hit, things haven’t been all bad—at least, not from the perspective of a major R&D player like Genentech. “There’s an enormous number of silver linings” that have come out of the pandemic, CEO Alexander Hardy said in an interview that aired Monday as part of Fierce JPM Week. read more By Eric Sagonowsky President Donald Trump's Operation Warp Speed promised 20 million COVID-19 vaccines administered to Americans by the end of 2020. Halfway into January, only 6.7 million have been. President-elect Biden says he has a plan for speeding it up—and ex-FDA chief Scott Gottlieb approves. read more By Robert King Universal Health Services reported a major cyberattack back in late September led to a decline in patient volume due to the outage. read more By Arlene Weintraub Interferon increases levels of the cell surface protein ACE2, which serves as the entry point for COVID-19, raising concerns that Synairgen and others developing inhaled interferon-based treatments might ultimately fail. Now, a U.K. team has discovered interferon only raises levels of a short form of ACE2 that may actually be protective. read more By Heather Landi Teladoc expects 2020 revenue to reach $1.1 billion, doubling its 2019 revenue of $553 million, driven by surging demand for virtual care solutions. With early commercial traction, the company is expanding its virtual primary care program this month with multiple partners, including large employers and health plans. read more By Paige Minemyer Centene Corporation CEO Michael Neidorff said the company is expecting care utilization to normalize but is planning for a different mix of services as COVID-19 cases surge. read more By Fraiser Kansteiner Merck KGaA snapped up German mRNA manufacturer AmpTec in a bid to beef up development and production of drugs and vaccines—including those for COVID-19—in the hot-and-happening field. The German drugmaker plans to scale up mRNA at AmpTec’s site in Hamburg, Germany, and its own home base in Darmstadt. read more |
